ITRM (ITRM)
Iterum Therapeutics plc
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
IEIterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments.
The company operates across Ireland, Bermuda, and the United States.
Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.
Leadership
Beth P. Hecht
Director
Corey N. Fishman
President, Chief Executive Officer & Director
David G. Kelly
Director
Joseph J. Whalen
Director
Employees
9
Country
IE
Sector
Healthcare
Website
iterumtx.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Dunne Michael W. | Director | Purchase | 6.0K | $2.2K | Nov 18, 2025 |
| Dunne Michael W. | Director | Purchase | 15.0K | $10.9K | Aug 8, 2025 |
 Coyne Christine | Chief Commercial Officer | Grant/Award | 200.0K | -- | Jul 1, 2025 |
 HUNT RONALD | Director | Other | 0 | -- | Jan 13, 2025 |
| HUNT RONALD | Director | Other | 0 | -- | Jan 13, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
Armistice Capital, LLC · may incl. warrants· filed Feb 2025 | 1.4M | 5.0% | 13G |
 Dunne Michael W. Director | 241.0K | -- | FORM 4 |
BARCLAYS PLC | 10.8K | -- | 13F |
Cypress Capital Management LLC | 66 | -- | 13F |
Insiders
- Dunne Michael W.Director
- Coyne ChristineChief Commercial Officer
- HUNT RONALDDirector
Top institutional holders
IE30d Avg
--
60d Avg
--
90d Avg
--